Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review
2020 · Health and Quality of Life Outcomes · 32 citations
https://doi.org/10.1186/s12955-020-01407-y
E
Evelien Bergrath
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
18
Papers
139
Citations
5
h-index
4
i10-index
Evelien Bergrath is an academic researcher from Regeneron (United States). The author has contributed to research in topics: Atrial Fibrillation Management and Outcomes & Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors. The author has an h-index of 5, co-authored 16 publications.
ORCID: 0000-0002-4351-4170Papers by this author
worksA Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation
2020 · Clinical and Applied Thrombosis/Hemostasis · 25 citations
https://doi.org/10.1177/1076029619898764
Real-world Evidence Comparing Oral Anticoagulants in non-valvular Atrial Fibrillation: A Systematic Review and Network meta-analysis
2022 · Future Cardiology · 25 citations
https://doi.org/10.2217/fca-2021-0120
P-415 Indirect Comparison of Linvoseltamab Versus Talquetamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Clinical Lymphoma Myeloma & Leukemia · 3 citations
https://doi.org/10.1016/s2152-2650(24)02317-6
P-403 Indirect Comparison of Linvoseltamab Versus Selinexor Plus Dexamethasone for Penta-Exposed Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Clinical Lymphoma Myeloma & Leukemia · 1 citations
https://doi.org/10.1016/s2152-2650(24)02305-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat